Advanced Hepatocellular Carcinoma (HCC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Advanced Hepatocellular Carcinoma (HCC) Market Outlook
Thelansis’s “Advanced Hepatocellular
Carcinoma (HCC) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2024 To 2034" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Advanced Hepatocellular Carcinoma
(HCC) treatment modalities options for eight major markets (USA, Germany,
France, Italy, Spain, UK, Japan, and China).
Advanced
Hepatocellular Carcinoma (HCC) Overview
Hepatocellular
Carcinoma (HCC) is the most common type of primary liver cancer with liver
cirrhosis, which develops following long periods of chronic liver disease.
Cirrhosis is characterized by a decrease in hepatocyte proliferation,
indicating exhaustion of the regenerative capacity of the liver. It increases
fibrous tissue and the destruction of liver cells, which may ultimately lead to
the development of cancerous nodules. Approximately 70%–90% of patients with
HCC have an established background of chronic liver disease and cirrhosis,
including chronic infection with hepatitis B virus (HBV), hepatitis C virus
(HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). Half
of all cases of HCC are associated with hepatitis B virus infection, with a
further 25% associated with hepatitis C virus. Unresectable HCC is clinically a
heterogeneous group of patients, including those with the intermediate stage
(BCLC B) and advanced stage (BCLC C).
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment